$ATYR
aTyr Pharma Inc

2017 Q4 Form 10-K Financial Statement

#000156459018006333 Filed on March 20, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.890M $17.08M $3.380M
YoY Change 74.26% 13.19% -11.29%
% of Gross Profit
Research & Development $5.310M $30.07M $9.140M
YoY Change -41.9% -29.83% -27.86%
% of Gross Profit
Depreciation & Amortization $160.0K $713.0K $220.0K
YoY Change -27.27% -20.78% -4.35%
% of Gross Profit
Operating Expenses $11.20M $47.15M $12.53M
YoY Change -10.59% -18.63% -24.0%
Operating Profit -$47.15M
YoY Change -18.63%
Interest Expense -$60.00K
YoY Change 50.0%
% of Operating Profit
Other Income/Expense, Net -$270.0K -$1.062M
YoY Change -3050.0%
Pretax Income -$11.47M -$48.21M -$12.62M
YoY Change -9.11% -16.75% -23.47%
Income Tax $0.00 $0.00 -$50.00K
% Of Pretax Income
Net Earnings -$11.47M -$48.21M -$12.57M
YoY Change -8.69% -16.68% -23.81%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$5.385M -$26.20M -$7.438M
COMMON SHARES
Basic Shares Outstanding 23.72M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.12M $85.10M $72.15M
YoY Change 17.98% 18.03% -24.48%
Cash & Equivalents $21.09M $21.10M $38.39M
Short-Term Investments $64.03M $64.00M $33.76M
Other Short-Term Assets $1.900M $1.900M $2.600M
YoY Change -26.92% -26.92% 8.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $86.99M $87.00M $74.80M
YoY Change 16.29% 16.31% -23.63%
LONG-TERM ASSETS
Property, Plant & Equipment $2.280M $2.300M $1.421M
YoY Change 60.45% 64.29% -20.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $4.000M
YoY Change -100.0% -100.0% -86.58%
Other Assets $90.00K $100.0K $333.0K
YoY Change -72.97% -66.67% 182.2%
Total Long-Term Assets $2.370M $2.400M $5.724M
YoY Change -58.6% -57.89% -81.96%
TOTAL ASSETS
Total Short-Term Assets $86.99M $87.00M $74.80M
Total Long-Term Assets $2.370M $2.400M $5.724M
Total Assets $89.36M $89.40M $80.52M
YoY Change 10.97% 11.06% -37.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.276M $2.300M $2.606M
YoY Change -12.66% -11.54% -32.7%
Accrued Expenses $3.103M $3.100M $5.450M
YoY Change -43.06% -43.64% 18.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.012M $5.000M $339.0K
YoY Change 1378.47% 1566.67% -89.93%
Total Short-Term Liabilities $10.39M $10.40M $8.525M
YoY Change 21.89% 22.35% -29.82%
LONG-TERM LIABILITIES
Long-Term Debt $14.72M $14.70M $9.198M
YoY Change 60.02% 59.78% 417.91%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $14.72M $14.70M $9.198M
YoY Change 60.02% 59.78% 291.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.39M $10.40M $8.525M
Total Long-Term Liabilities $14.72M $14.70M $9.198M
Total Liabilities $25.11M $25.10M $17.72M
YoY Change 41.68% 41.81% 22.27%
SHAREHOLDERS EQUITY
Retained Earnings -$264.2M -$216.0M
YoY Change 22.32% 36.59%
Common Stock $30.00K $278.9M
YoY Change -99.99% 2.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.25M $64.20M $62.80M
YoY Change
Total Liabilities & Shareholders Equity $89.36M $89.40M $80.52M
YoY Change 10.97% 11.06% -37.9%

Cashflow Statement

Concept 2017 Q4 2017 2016 Q4
OPERATING ACTIVITIES
Net Income -$11.47M -$48.21M -$12.57M
YoY Change -8.69% -16.68% -23.81%
Depreciation, Depletion And Amortization $160.0K $713.0K $220.0K
YoY Change -27.27% -20.78% -4.35%
Cash From Operating Activities -$10.30M -$42.36M -$11.69M
YoY Change -11.89% -19.86% 18.8%
INVESTING ACTIVITIES
Capital Expenditures -$160.0K $1.312M -$50.00K
YoY Change 220.0% 118.67% -54.55%
Acquisitions
YoY Change
Other Investing Activities -$3.370M -$26.33M $8.650M
YoY Change -138.96% -177.15% 115.17%
Cash From Investing Activities -$3.530M -$27.64M $8.600M
YoY Change -141.05% -182.43% 119.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $186.0K
YoY Change 830.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.160M 52.70M 7.150M
YoY Change -27.83% 1022.08% -755.96%
NET CHANGE
Cash From Operating Activities -10.30M -42.36M -11.69M
Cash From Investing Activities -3.530M -27.64M 8.600M
Cash From Financing Activities 5.160M 52.70M 7.150M
Net Change In Cash -8.670M -17.30M 4.060M
YoY Change -313.55% 18.17% -157.83%
FREE CASH FLOW
Cash From Operating Activities -$10.30M -$42.36M -$11.69M
Capital Expenditures -$160.0K $1.312M -$50.00K
Free Cash Flow -$10.14M -$43.68M -$11.64M
YoY Change -12.89% -18.3% 19.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29789162
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23744832
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29789162
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23744832
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34504000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
65000
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-29000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4002000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5012000
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14719000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9198000
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
328519000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
278832000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-120000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-76000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264186000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-215979000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
64245000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
62801000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
89355000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80524000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
339000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8525000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-357000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6784000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1062000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-47145000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47973000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48251000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
535000
CY2015 life Reclassification Of Convertible Preferred Stock Warrant Liability To Additional Paid In Capital
ReclassificationOfConvertiblePreferredStockWarrantLiabilityToAdditionalPaidInCapital
290000
CY2015 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-29000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1062000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
36000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48207000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57904000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-49000
CY2015 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
15000
CY2017 life Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-48207000
CY2016 life Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-57855000
CY2015 life Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-47988000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.44
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.03
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23681019
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15838353
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
95000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-171000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57760000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-48144000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-91010000
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
171284000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75903000
CY2015 life Adjustments To Additional Paid In Capital And Stockholder Note Receivable
AdjustmentsToAdditionalPaidInCapitalAndStockholderNoteReceivable
60000
CY2015 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1411000
CY2015 life Increase Decrease To Additional Paid In Capital Changes To Share Repurchase Liability
IncreaseDecreaseToAdditionalPaidInCapitalChangesToShareRepurchaseLiability
-120000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4856000
CY2015 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
15000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
115050000
CY2016 life Stock Issued During Period Value Stock Options Exercised And Release Of Restricted Stock Units
StockIssuedDuringPeriodValueStockOptionsExercisedAndReleaseOfRestrictedStockUnits
20000
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
217000
CY2016 life Increase Decrease To Additional Paid In Capital Changes To Share Repurchase Liability
IncreaseDecreaseToAdditionalPaidInCapitalChangesToShareRepurchaseLiability
102000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5029000
CY2017 life Stock Issued During Period Value Stock Options Exercised And Release Of Restricted Stock Units
StockIssuedDuringPeriodValueStockOptionsExercisedAndReleaseOfRestrictedStockUnits
186000
CY2017 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
175000
CY2017 life Stock Issued During Period Value Private Placement Net Of Offering Costs
StockIssuedDuringPeriodValuePrivatePlacementNetOfOfferingCosts
42239000
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
263000
CY2017 life Increase Decrease To Additional Paid In Capital Changes To Share Repurchase Liability
IncreaseDecreaseToAdditionalPaidInCapitalChangesToShareRepurchaseLiability
48000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
713000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
900000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
869000
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1411000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6784000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5029000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4856000
CY2017 us-gaap Accretion Expense
AccretionExpense
192000
CY2016 us-gaap Accretion Expense
AccretionExpense
173000
CY2015 us-gaap Accretion Expense
AccretionExpense
297000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-14000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-531000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-789000
CY2017 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-130000
CY2016 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-315000
CY2015 life Increase Decrease In Deferred Rent Credit
IncreaseDecreaseInDeferredRentCredit
-295000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-761000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
421000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
666000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2491000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-932000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3944000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-42364000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-52861000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-36797000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1312000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
600000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
664000
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
77672000
CY2016 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
28089000
CY2015 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
109445000
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
51347000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
62216000
CY2015 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
38115000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-27637000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
33527000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-71994000
CY2015 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
75648000
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
76902000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
186000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
604000
CY2017 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
175000
CY2016 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
143000
CY2017 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
9866000
CY2016 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
9736000
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
42477000
CY2016 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5202000
CY2015 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3237000
CY2015 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2000000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
52704000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4697000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
147917000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14637000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
39126000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53025000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13899000
CY2017 us-gaap Interest Paid
InterestPaid
1000000
CY2016 us-gaap Interest Paid
InterestPaid
225000
CY2015 us-gaap Interest Paid
InterestPaid
925000
CY2017 life Issuance Of Warrants In Connection With Borrowings
IssuanceOfWarrantsInConnectionWithBorrowings
263000
CY2016 life Issuance Of Warrants In Connection With Borrowings
IssuanceOfWarrantsInConnectionWithBorrowings
217000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Our consolidated financial statements are prepared in accordance with generally accepted accounting principles (GAAP). The preparation of our consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. The most significant estimates in our consolidated financial statements relate to the fair value of equity issuances and awards, and clinical trials and research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.17%;">Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of cash, cash equivalents and investment securities. We have established guidelines regarding diversification of investments and their maturities, which are designed to maintain principal and maximize liquidity. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have not experienced any losses in such accounts and we believe that we are not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p></div>
CY2017 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
64000000
CY2017 life Adjustment Of Amortized Cost And Fair Value Of Investment Securities
AdjustmentOfAmortizedCostAndFairValueOfInvestmentSecurities
100000
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
3685
CY2016 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
25984
CY2015 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
61814
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4250049
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2668613
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-48207000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-57855000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47988000
CY2017 life Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
25803538
CY2016 life Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
23707003
CY2015 life Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
15900167
CY2017Q4 us-gaap Preferred Stock Redemption Amount
PreferredStockRedemptionAmount
0
CY2017 us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
The first tranche of $10.0 million was funded in November 2016 (Term A Loan). Under the Term A Loan, we received cash proceeds of $7.3 million, net of a $2.6 million repayment of the principal, accrued interest and the $0.5 million final payment under our previous $10.0 million loan and security agreement with SVB (SVB Loan). We did not pay any termination or other fees in connection with the repayment of amounts due under the SVB Loan.
CY2017Q1 life Lease Agreement Extended Term
LeaseAgreementExtendedTerm
P2Y
CY2017Q1 life Noncancelable Operating Leases Term Of Extension
NoncancelableOperatingLeasesTermOfExtension
2019-05
CY2017Q2 life Additional Lease Facility
AdditionalLeaseFacility
7411
CY2017Q2 life Noncancelable Operating Leases Term Of Extension
NoncancelableOperatingLeasesTermOfExtension
2019-05
CY2017Q2 life Noncancelable Operating Leases Additional Commitment
NoncancelableOperatingLeasesAdditionalCommitment
700000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
900000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1108000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
75289
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
830759
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
420000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1528000
CY2017 life Registration Statement Filing Date
RegistrationStatementFilingDate
2016-06
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4014988
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1508119
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
34000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.34
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.29
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
100000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
13000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4617059
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2220670
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.73
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.51
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.47
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
7.99
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.52
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.01
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M13D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M13D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M23D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1370000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1370000
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1070000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.85
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1900000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6000000
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6682708
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
24128073
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5131515
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-47712000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-57096000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-47490000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-495000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-808000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-483000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16390000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-19687000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16311000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-13000
CY2017 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
1311000
CY2016 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
675000
CY2015 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
865000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2286000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6800000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2674000
CY2017 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
914000
CY2016 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
2720000
CY2015 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
1070000
CY2017 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
87000
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
141000
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
84000
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-25000
CY2015 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
3551000
CY2017 life Income Tax Reconciliation Tax Cuts And Jobs Act Of2017
IncomeTaxReconciliationTaxCutsAndJobsActOf2017
27933000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-11531000
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
22902000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13415000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59726000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
71149000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27226000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33713000
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
16218000
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
21624000
CY2017Q4 life Deferred Tax Assets Tax Credit Carryforwards Research And Other State
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOtherState
11229000
CY2016Q4 life Deferred Tax Assets Tax Credit Carryforwards Research And Other State
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOtherState
9227000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2210000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3874000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2843000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2711000
CY2017 life Period Of Change In Ownership
PeriodOfChangeInOwnership
P3Y
CY2017 life Percentage Of Change In Ownership
PercentageOfChangeInOwnership
0.50
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13000000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5033000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1106000
CY2017 life Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
-189000
CY2016 life Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
1890000
CY2015 life Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
2404000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3747000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6077000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1523000
CY2017Q4 us-gaap Increase In Unrecognized Tax Benefits Is Reasonably Possible
IncreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017 life Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
27900000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
13211000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
11907000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
10827000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
11200000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-13405000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-12138000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-11190000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-11474000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
16115000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
15433000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
13865000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
12527000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-16087000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-15383000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-13819000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-12566000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53

Files In Submission

Name View Source Status
0001564590-18-006333-index-headers.html Edgar Link pending
0001564590-18-006333-index.html Edgar Link pending
0001564590-18-006333.txt Edgar Link pending
0001564590-18-006333-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018032020243229219921.jpg Edgar Link pending
g2018032020243232119922.jpg Edgar Link pending
g2018032020243233219923.jpg Edgar Link pending
g2018032020243233819924.jpg Edgar Link pending
g2018032020243236019925.jpg Edgar Link pending
g2018032020243236519926.jpg Edgar Link pending
g2018032020243237719927.jpg Edgar Link pending
g2018032020243238919928.jpg Edgar Link pending
g2018032020243239919929.jpg Edgar Link pending
g2018032020244122519930.jpg Edgar Link pending
life-10k_20171231.htm Edgar Link pending
life-20171231.xml Edgar Link completed
life-20171231.xsd Edgar Link pending
life-20171231_cal.xml Edgar Link unprocessable
life-20171231_def.xml Edgar Link unprocessable
life-20171231_lab.xml Edgar Link unprocessable
life-20171231_pre.xml Edgar Link unprocessable
life-ex1021_1232.htm Edgar Link pending
life-ex1022_637.htm Edgar Link pending
life-ex1023_636.htm Edgar Link pending
life-ex231_7.htm Edgar Link pending
life-ex311_6.htm Edgar Link pending
life-ex312_12.htm Edgar Link pending
life-ex321_11.htm Edgar Link pending
life-ex322_10.htm Edgar Link pending
life-ex48_470.htm Edgar Link pending
life-ex49_469.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending